HEMOCHROMATOSIS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)

Hemochromatosis Market, By Type (Primary Hemochromatosis, Secondary Hemochromatosis), By Diagnosis Method (Blood Tests, Imaging Techniques (Magnetic Resonance Imaging, Computed Tomography, Liver Biopsy, and Genetic Testing), By Treatment Type (Phlebotomy, Chelation Therapy, Dietary Management, and Others), By Age Group (Pediatric, Adult, and Geriatric), By End User (Hospitals, Diagnostic Laboratories, Surgical Centers, and Home Care Settings), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

On August 14, 2024, Australia introduced the world's first online registry for haemochromatosis patients. This platform collects anonymous health data to aid research and improve treatments for this common genetic disorder. Developed by Haemochromatosis Australia and several universities, the registry allows patients to contribute by completing an online health questionnaire. Researchers can access this data to advance understanding and care of haemochromatosis.
A study published in March 2024 by the University of Exeter, analyzing data from over 450,000 individuals in the UK Biobank, found that people with two copies of the C282Y genetic variant linked to haemochromatosis face higher risks of liver disease, joint replacements, and certain neurological conditions as they age.
In October 2021, Protagonist Therapeutics, a biopharmaceutical company, announced that data from its Phase 2 study of rusfertide for hereditary hemochromatosis was selected for oral presentation at The Liver Meeting 2021, hosted by the American Association for the Study of Liver Diseases (AASLD). Mr. Dinesh Patel, Ph.D., President and CEO, highlighted that the findings establish clinical proof-of-concept for rusfertide in treating hereditary hemochromatosis.